Search

Your search keyword '"Coutte, Laetitia"' showing total 13 results
Start Over Author "Coutte, Laetitia"
13 results on '"Coutte, Laetitia"'

1. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Author

Valiente, Adoración, de Cueto, Marina, Rodríguez, Ángel, Molina, José, Fischer, Julia, Paul, Gregor, Gallien, Sébastien, Fihman, Vincent, Lacasse, Marion, Coustillères, Francois, Becker, Christian, Fuchs, André, Morata, Laura, Weis, Sebastian, Ponscarme, Diane, Khatchatourian, Lydie, Rouveix, Elisabeth, Merrien, Dominique, Lecomte, Raphaël, Veenemans, Jacobien, Vilchez, Helem H., Kessel, Johanna, Bonten, Marc J.M., Rupp, Jan, Hocqueloux, Laurent, Lucht, Frederic, Stahl, Jean-Paul, Vlek, Anne, Prinz-Langenohl, Reinhild, Tolsma, Violaine, Kaasch, Achim J, López-Cortés, Luis Eduardo, Rodríguez-Baño, Jesús, Cisneros, José Miguel, Dolores Navarro, M, Fätkenheuer, Gerd, Jung, Norma, Rieg, Siegbert, Lepeule, Raphaël, Coutte, Laetitia, Bernard, Louis, Lemaignen, Adrien, Kösters, Katrin, MacKenzie, Colin R, Soriano, Alex, Hagel, Stefan, Fantin, Bruno, Lafaurie, Matthieu, Talarmin, Jean-Philippe, Dinh, Aurélien, Guimard, Thomas, Boutoille, David, Welte, Tobias, Reuter, Stefan, Kluytmans, Jan, Martin, Maria Luisa, Forestier, Emmanuel, Stocker, Hartmut, Vitrat, Virginie, Tattevin, Pierre, Rommerskirchen, Anna, Noret, Marion, Adams, Anne, Kern, Winfried V, Hellmich, Martin, and Seifert, Harald

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Author

Kaasch, Achim J, primary, López-Cortés, Luis Eduardo, additional, Rodríguez-Baño, Jesús, additional, Cisneros, José Miguel, additional, Dolores Navarro, M, additional, Fätkenheuer, Gerd, additional, Jung, Norma, additional, Rieg, Siegbert, additional, Lepeule, Raphaël, additional, Coutte, Laetitia, additional, Bernard, Louis, additional, Lemaignen, Adrien, additional, Kösters, Katrin, additional, MacKenzie, Colin R, additional, Soriano, Alex, additional, Hagel, Stefan, additional, Fantin, Bruno, additional, Lafaurie, Matthieu, additional, Talarmin, Jean-Philippe, additional, Dinh, Aurélien, additional, Guimard, Thomas, additional, Boutoille, David, additional, Welte, Tobias, additional, Reuter, Stefan, additional, Kluytmans, Jan, additional, Martin, Maria Luisa, additional, Forestier, Emmanuel, additional, Stocker, Hartmut, additional, Vitrat, Virginie, additional, Tattevin, Pierre, additional, Rommerskirchen, Anna, additional, Noret, Marion, additional, Adams, Anne, additional, Kern, Winfried V, additional, Hellmich, Martin, additional, Seifert, Harald, additional, Valiente, Adoración, additional, de Cueto, Marina, additional, Rodríguez, Ángel, additional, Molina, José, additional, Fischer, Julia, additional, Paul, Gregor, additional, Gallien, Sébastien, additional, Fihman, Vincent, additional, Lacasse, Marion, additional, Coustillères, Francois, additional, Becker, Christian, additional, Fuchs, André, additional, Morata, Laura, additional, Weis, Sebastian, additional, Ponscarme, Diane, additional, Khatchatourian, Lydie, additional, Rouveix, Elisabeth, additional, Merrien, Dominique, additional, Lecomte, Raphaël, additional, Veenemans, Jacobien, additional, Vilchez, Helem H., additional, Kessel, Johanna, additional, Bonten, Marc J.M., additional, Rupp, Jan, additional, Hocqueloux, Laurent, additional, Lucht, Frederic, additional, Stahl, Jean-Paul, additional, Vlek, Anne, additional, Prinz-Langenohl, Reinhild, additional, and Tolsma, Violaine, additional

Published
2024
Full Text
View/download PDF

6. Prognostic Factors in Syphilitic Uveitis

Author

Hoogewoud, Florence, Frumholtz, Laure, Loubet, Paul, Charlier, Caroline, Blanche, Philippe, Lebeaux, David, Benhaddou, Nadjet, Sedira, Neila, Coutte, Laetitia, Vanhaecke, Clelia, Launay, Odile, Le Jeunne, Claire, Héron, Emmanuel, Monnet, Dominique, Lortholary, Olivier, Sahel, José-Alain, Dupin, Nicolas, Brézin, Antoine, Errera, Marie-Hélène, Salah, Sawsen, and Groh, Matthieu

Published
2017
Full Text
View/download PDF

7. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

Author

Le Burel, Sébastien, Champiat, Stéphane, Mateus, Christine, Marabelle, Aurélien, Michot, Jean-Marie, Robert, Caroline, Belkhir, Rakiba, Soria, Jean-Charles, Laghouati, Salim, Voisin, Anne-Laure, Fain, Olivier, Mékinian, Arsène, Coutte, Laetitia, Szwebel, Tali-Anne, Dunogeant, Laetitia, Lioger, Bertrand, Luxembourger, Cécile, Mariette, Xavier, and Lambotte, Olivier

Published
2017
Full Text
View/download PDF

12. [2016 review on catastrophic antiphospholipid syndrome].

Author

Costedoat-Chalumeau N, Coutte L, Le Guern V, Morel N, Leroux G, Paule R, Mouthon L, and Piette JC

Subjects
Catastrophic Illness, Diagnosis, Differential, Humans, Prognosis, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome epidemiology, Antiphospholipid Syndrome physiopathology, Antiphospholipid Syndrome therapy
Abstract

The catastrophic antiphospholipid syndrome (CAPS) develops in at least 1% of patients with antiphospholipid syndrome, either primary or associated with systemic lupus erythematosus. CAPS reveals the antiphospholipid syndrome in about 50% of cases. The CAPS is characterized by rapidly-progressive widespread thromboses mainly affecting the microvasculature in the presence of antiphospholipid antibodies. In a few days, the patients develop multiorgan failure with renal insufficiency with severe hypertension, pulmonary, cerebral, cardiac, digestive and/or cutaneous involvement. The vital prognosis is frequently engaged. CAPS is often precipitated by infectious diseases, surgical procedures and/or withdrawal or modification of the anticoagulation. CAPS overall mortality rate has decreased and is currently below 30%. The main differential diagnoses are other thrombotic microangiopathies, and heparin-induced thrombocytopenia. The treatment of CAPS consists of the association of anticoagulation and steroids, plus plasma exchange and/or intravenous immunoglobulins. Cyclophosphamide is added only in patients with active systemic lupus erythematosus. The potential contribution of some additional therapies (rituximab, eculizumab or sirolimus) needs to be assessed. The prevention of CAPS is essential and is based upon the adequate management of the perioperative period when surgery cannot be avoided, the prompt treatment and the prevention with immunization of infections and the education of patients with antiphospholipid syndrome, especially for the management of oral anticoagulants., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)

Published
2016
Full Text
View/download PDF

13. [PI3K-AKT-mTOR pathway and cancer].

Author

Coutte L, Dreyer C, Sablin MP, Faivre S, and Raymond E

Subjects
Everolimus, Humans, Kidney Neoplasms blood supply, Kidney Neoplasms metabolism, Neovascularization, Pathologic drug therapy, Neovascularization, Pathologic etiology, Oncogene Protein v-akt physiology, Phosphatidylinositol 3-Kinases physiology, Signal Transduction physiology, Sirolimus analogs & derivatives, Sirolimus pharmacology, TOR Serine-Threonine Kinases physiology, Carcinoma, Renal Cell drug therapy, Kidney Neoplasms drug therapy, Lymphoma, Mantle-Cell drug therapy, Oncogene Protein v-akt antagonists & inhibitors, Phosphoinositide-3 Kinase Inhibitors, Signal Transduction drug effects, TOR Serine-Threonine Kinases antagonists & inhibitors
Abstract

PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results